BioNTech (NASDAQ:BNTX) CEO Sells $1,441,350.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 15,000 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00. Following the completion of the sale, the chief executive officer directly owned 553,209 shares of the company’s stock, valued at $53,157,852.81. The trade was a 2.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Down 2.6%

NASDAQ:BNTX opened at $96.06 on Friday. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a market cap of $24.29 billion, a PE ratio of -12.27 and a beta of 1.29. The company’s 50 day moving average is $97.38 and its two-hundred day moving average is $94.93.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company’s quarterly revenue was down 59.5% on a year-over-year basis. During the same period in the prior year, the business posted ($1.60) EPS. Analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several large investors have recently made changes to their positions in the company. Flossbach Von Storch SE acquired a new stake in BioNTech during the second quarter valued at $207,142,000. BNP Paribas Financial Markets increased its holdings in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares in the last quarter. First Trust Advisors LP raised its position in shares of BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of BioNTech during the 2nd quarter worth about $39,385,000. Finally, SEB Asset Management AB acquired a new stake in shares of BioNTech during the 1st quarter valued at about $17,804,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BNTX has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. Finally, Morgan Stanley decreased their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.